[go: up one dir, main page]

FR2873585B1 - Nouvelles formulations galeniques de principes actifs - Google Patents

Nouvelles formulations galeniques de principes actifs

Info

Publication number
FR2873585B1
FR2873585B1 FR0408269A FR0408269A FR2873585B1 FR 2873585 B1 FR2873585 B1 FR 2873585B1 FR 0408269 A FR0408269 A FR 0408269A FR 0408269 A FR0408269 A FR 0408269A FR 2873585 B1 FR2873585 B1 FR 2873585B1
Authority
FR
France
Prior art keywords
active principles
galenic formulations
new galenic
new
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0408269A
Other languages
English (en)
Other versions
FR2873585A1 (fr
Inventor
Jean Pachot
Chicq Serge Segot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0408269A priority Critical patent/FR2873585B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to PCT/FR2005/001853 priority patent/WO2006018501A1/fr
Priority to KR1020077001445A priority patent/KR20070046819A/ko
Priority to RU2007107199/15A priority patent/RU2381789C2/ru
Priority to CNA2005800268156A priority patent/CN101001608A/zh
Priority to EP05790808A priority patent/EP1771154A1/fr
Priority to NZ552715A priority patent/NZ552715A/en
Priority to US11/572,402 priority patent/US20080193519A1/en
Priority to BRPI0513622-9A priority patent/BRPI0513622A/pt
Priority to JP2007521988A priority patent/JP2008508191A/ja
Priority to CA002579449A priority patent/CA2579449A1/fr
Priority to AU2005273839A priority patent/AU2005273839A1/en
Priority to MX2007001141A priority patent/MX2007001141A/es
Priority to TW094125195A priority patent/TW200616640A/zh
Publication of FR2873585A1 publication Critical patent/FR2873585A1/fr
Application granted granted Critical
Publication of FR2873585B1 publication Critical patent/FR2873585B1/fr
Priority to IL180714A priority patent/IL180714A0/en
Priority to NO20070354A priority patent/NO20070354L/no
Priority to ZA200700553A priority patent/ZA200700553B/en
Priority to MA29627A priority patent/MA28748B1/fr
Priority to US12/870,250 priority patent/US20110104268A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0408269A 2004-07-20 2004-07-27 Nouvelles formulations galeniques de principes actifs Expired - Fee Related FR2873585B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR0408269A FR2873585B1 (fr) 2004-07-27 2004-07-27 Nouvelles formulations galeniques de principes actifs
AU2005273839A AU2005273839A1 (en) 2004-07-27 2005-07-20 Galenic applications of self-emulsifying mixtures of lipidic excipients
RU2007107199/15A RU2381789C2 (ru) 2004-07-27 2005-07-20 Применение самоэмульгирующихся смесей липидных эксципиентов в галеновых препаратах
CNA2005800268156A CN101001608A (zh) 2004-07-27 2005-07-20 脂类赋形剂的自乳化混合物的药物应用
EP05790808A EP1771154A1 (fr) 2004-07-27 2005-07-20 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
NZ552715A NZ552715A (en) 2004-07-27 2005-07-20 Galenic applications of self-emulsifying mixtures of lipidic excipients
US11/572,402 US20080193519A1 (en) 2004-07-20 2005-07-20 Galenic Applications of Self-Emulsifying Mixtures of Lipidic Excipients
MX2007001141A MX2007001141A (es) 2004-07-27 2005-07-20 Aplicaciones galenicas de mezclas auto-emulsionantes de excipientes lipidicos.
KR1020077001445A KR20070046819A (ko) 2004-07-27 2005-07-20 지질 부형제의 자가 유화 혼합물의 갈레노스 용도
CA002579449A CA2579449A1 (fr) 2004-07-27 2005-07-20 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
PCT/FR2005/001853 WO2006018501A1 (fr) 2004-07-27 2005-07-20 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
JP2007521988A JP2008508191A (ja) 2004-07-27 2005-07-20 脂質賦形剤の自己乳化混合物のガレノス式適用
BRPI0513622-9A BRPI0513622A (pt) 2004-07-27 2005-07-20 aplicação de combinações auto-emulsificantes (seeds) de excipientes lipìdicos, de surfactantes; composição farmacêutica contendo um princìpio ativo e uma combinação auto-emulsificante (seeds) de excipientes lipìdicos, de surfactantes; e processo para a preparação de combinações auto-emulsificantes (seeds) de excipientes lipìdios, de surfactantes
TW094125195A TW200616640A (en) 2004-07-27 2005-07-26 Novel pharmaceutical formulations of active principles
IL180714A IL180714A0 (en) 2004-07-27 2007-01-15 Galenic applications of self-emulsifying mixtures of lipidic excipients
NO20070354A NO20070354L (no) 2004-07-27 2007-01-19 Galeniske anvendelser om selvemulgerende blandinger av lipideksipienter
ZA200700553A ZA200700553B (en) 2004-07-27 2007-01-19 Galenic applications of self-emulsifying mixtures of lipidic excipients
MA29627A MA28748B1 (fr) 2004-07-27 2007-01-23 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
US12/870,250 US20110104268A1 (en) 2004-07-27 2010-08-27 Galenic applications of self-emulsifying mixtures of lipidic excipients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408269A FR2873585B1 (fr) 2004-07-27 2004-07-27 Nouvelles formulations galeniques de principes actifs

Publications (2)

Publication Number Publication Date
FR2873585A1 FR2873585A1 (fr) 2006-02-03
FR2873585B1 true FR2873585B1 (fr) 2006-11-17

Family

ID=34951660

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408269A Expired - Fee Related FR2873585B1 (fr) 2004-07-20 2004-07-27 Nouvelles formulations galeniques de principes actifs

Country Status (18)

Country Link
US (2) US20080193519A1 (fr)
EP (1) EP1771154A1 (fr)
JP (1) JP2008508191A (fr)
KR (1) KR20070046819A (fr)
CN (1) CN101001608A (fr)
AU (1) AU2005273839A1 (fr)
BR (1) BRPI0513622A (fr)
CA (1) CA2579449A1 (fr)
FR (1) FR2873585B1 (fr)
IL (1) IL180714A0 (fr)
MA (1) MA28748B1 (fr)
MX (1) MX2007001141A (fr)
NO (1) NO20070354L (fr)
NZ (1) NZ552715A (fr)
RU (1) RU2381789C2 (fr)
TW (1) TW200616640A (fr)
WO (1) WO2006018501A1 (fr)
ZA (1) ZA200700553B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867323A1 (fr) * 2006-06-13 2007-12-19 Farmatron Ltd. Formulations pharmaceutiques avec pénétration améliorée à travers des barrières biologiques
KR101493546B1 (ko) * 2007-08-21 2015-02-16 바실리어 파마슈티카 아게 항균 조성물
ES2661812T3 (es) 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
JP2013209294A (ja) * 2010-07-30 2013-10-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 液状医薬組成物
EP2782584B1 (fr) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
KR20210102936A (ko) * 2018-12-10 2021-08-20 헤일로 사이언스 엘엘씨 안정적인 마취제 제제 및 관련 복용량 형태
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
CN114246827B (zh) * 2022-01-04 2023-04-11 中山大学 一种鱼油微乳制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
FR2710535B1 (fr) * 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
EP0933367A1 (fr) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Dérivés d'acylguanidine comme inhibiteurs de résorbtion osseuse et comme antagonistes de récepteur vitronectine
EA003102B1 (ru) * 1998-01-23 2002-12-26 Авентис Фарма Дойчланд Гмбх Сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток, способ их получения, применение и фармацевтическая композиция
ATE327735T1 (de) * 1998-04-01 2006-06-15 Jagotec Ag Taxan-mikroemulsionen
EP1015046A2 (fr) * 1998-07-14 2000-07-05 Em Industries, Inc. Systemes d'apport de medicaments par microdispersion
GB0003685D0 (en) * 2000-02-17 2000-04-05 Univ Cardiff Sensitisation of cellular material
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CA2485430C (fr) * 2002-05-14 2011-12-06 Xenova Limited Procede de preparation d'un hydrate de derive d'acide anthranilique

Also Published As

Publication number Publication date
KR20070046819A (ko) 2007-05-03
RU2381789C2 (ru) 2010-02-20
AU2005273839A1 (en) 2006-02-23
US20080193519A1 (en) 2008-08-14
WO2006018501A8 (fr) 2007-03-01
EP1771154A1 (fr) 2007-04-11
ZA200700553B (en) 2008-05-28
JP2008508191A (ja) 2008-03-21
IL180714A0 (en) 2007-06-03
RU2007107199A (ru) 2008-09-10
MA28748B1 (fr) 2007-07-02
NZ552715A (en) 2010-12-24
CN101001608A (zh) 2007-07-18
BRPI0513622A (pt) 2008-05-13
MX2007001141A (es) 2007-04-19
FR2873585A1 (fr) 2006-02-03
US20110104268A1 (en) 2011-05-05
CA2579449A1 (fr) 2006-02-23
NO20070354L (no) 2007-04-17
TW200616640A (en) 2006-06-01
WO2006018501A1 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
NO20075628L (no) Farmasøytiske formuleringer
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
DK2060189T3 (da) Aktivstofholdige adsorbater
MA28490B1 (fr) Formulations galeniques de composes organiques
DK1750683T3 (da) Formuleringer med langvarig frigivelse
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
EP1981547A4 (fr) Formulations therapeutiques stables
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
PT1501534E (pt) Formulacoes farmaceuticas
ATE482618T1 (de) Wirkstoffkombinationen
MA29014B1 (fr) Formulations d'anticorps
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
DK1601359T3 (da) Væskeformige, farmaceutiske formuleringer af palonosetron
EP2046361A4 (fr) Composition d'amplification d'activité ostéogène
HRP20160866T1 (hr) Postupci primjene hipoglikemijskih sredstava
MX266708B (es) Formulaciones de microparticulas de pantoprazol.
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
CR9144A (es) Formulaciones de benzoxazoles sustituidos
ITMI20050729A1 (it) Nuova formulazione biologicamente attiva
NL1028193A1 (nl) Farmaceutisch werkzame verbindingen.
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
ITFI20050041A1 (it) Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
MA28846B1 (fr) Composition biologiquement active

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130329